Table 2.
All grades cardiovascular event comparison of nine VEGFR-TKIs
| AXI | |||||||||
|
1.00 (0.48, 2.07) |
CAB | ||||||||
|
0.51 (0.24, 1.08) |
0.52 (0.22, 1.19) |
LEN | |||||||
|
3.66 (1.82, 7.13) ƚ |
3.66 (1.63, 7.85) ƚ |
7.10 (3.18, 15.47) ƚ |
NIN | ||||||
|
1.35 (0.69, 2.69) |
1.36 (0.63, 2.91) |
2.64 (1.18, 5.98) ƚ |
0.37 (0.18, 0.79)* |
PAZ | |||||
| 8.06 (5.23, 13.02) ƚ |
8.16 (4.55, 14.56) ƚ |
15.72 (8.46, 30.11) ƚ |
2.22 (1.30, 3.86) ƚ |
5.94 (3.61, 9.94) ƚ |
PLA | ||||
|
1.76 (0.97, 3.36) |
1.77 (0.86, 3.74) |
3.43 (1.64, 7.53) ƚ |
0.49 (0.25, 0.99)* |
1.30 (0.67, 2.51) |
0.22 (0.14, 0.34)* |
REG | |||
|
1.60 (1.02, 2.51) ƚ |
1.61 (0.84, 2.99) |
3.11 (1.69, 5.74) ƚ |
0.44 (0.26, 0.75)* |
1.18 (0.66, 2.06) |
0.20 (0.15, 0.25)* |
0.91 (0.54, 1.49) |
SOR | ||
|
1.74 (1.03, 3.16)) ƚ |
1.76 (0.95, 3.31) |
3.40 (1.72, 7.09) ƚ |
0.48 (0.27, 0.89)* |
1.29 (0.71, 2.40) |
0.22 (0.15, 0.32)* |
0.99 (0.57, 1.77) |
1.10 (0.76, 1.66) |
SUN | |
|
0.64 (0.31, 1.32) |
0.64 (0.29, 1.43) |
1.24 (0.53, 2.90) |
0.18 (0.08, 0.38)* |
0.47 (0.22, 1.00) |
0.08 (0.04, 0.14)* |
0.36 (0.17, 0.72)* |
0.40 (0.21, 0.75)* |
0.36 (0.18, 0.70)* |
VAN |
Data presented with ORs (95% CrI) in the column-defining drug compared with the row-defining drug
OR odds ratio, CrI credible interval, PLA placebo, AXI axitinib, CAB cabozantinib, LEN lenvatinib, NIN nintedanib, PAZ pazopanib, REG regorafenib, SOR sorafenib, SUN sunitinib, VAN vandetanib
*ORs more than 1 favors row-defining drug
ƚ ORs less than 1 favors column-defining drug